Fiberoptic Bronchoscopy
Conditions
Interventions
DI:Dexmedetomidine nasal spray 2 sprays (50 ug)
D2:Dexmedetomidine nasal spray 3sprays (75 ug)
D3:Dexmedetomidine nasal spray 4 sprays (100 ug)
Sponsors
Affiliated Hospital of Shaoxing University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with American Society of Anesthesiologists (ASA) physical status I–III who agreed to participate in the study and provided written informed consent ; 2. Age 18–80 years, regardless of sex; 3. Peripheral oxygen saturation (SpO2) > 90% while breathing room air; 4. Patients scheduled to undergo elective painless fiberoptic bronchoscopy.
Exclusion criteria
Exclusion criteria: 1. Preexisting pulmonary diseases; 2. Severe obstructive sleep apnea syndrome, defined as an apnea–hypopnea index (AHI) > 40; 3. Body mass index (BMI) > 30 kg/m^2 ; 4. Patients with long-term use of psychotropic medications, alcohol abuse, or drug abuse; 5. Patients with severe visual or hearing impairment or difficulty in verbal communication; 6. Patients with obvious abnormalities in liver and kidney function or severe cardiopulmonary diseases; 7. Patients who are allergic or contraindicated to propofol, dexmedetomidine drugs, opioids, or any components of these medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of choking cough; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vital signs;Pittsburgh Sleep Quality Index;Quality of Recovery (QoR); | — |
Countries
China
Contacts
Public ContactBaozhu Cha
Affiliated Hospital of Shaoxing University
Outcome results
None listed